Transcript and protein profiling identifies signaling, growth arrest, apoptosis, and NF-κB survival signatures following GNRH receptor activation

Endocrine-Related Cancer

Volumn 20, Issue 1, 2013, Pages 123-136

  Meyer, Colette ^a   Sims, Andrew H ^a   Morgan, Kevin ^b,d   Harrison, Beth ^a   Muir, Morwenna ^a   Bai, Jianing ^a   Faratian, Dana ^a   Millar, Robert P ^a,c   Langdon, Simon P ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF PRETORIA   (South Africa)

^d UNIVERSITY OF HULL   (United Kingdom)

Author keywords

GnRh; NFkB; SCL60; Triptorelin; Xenograft

Indexed keywords

GONADORELIN RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; TRIPTORELIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL CULTURE; CELL CYCLE; CELL DIVISION; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; GENE CONTROL; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; GROWTH DISORDER; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; PROTEOMICS; TRANSCRIPTOMICS; TREATMENT DURATION; UPREGULATION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; ENZYME INHIBITORS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; IMMUNOENZYME TECHNIQUES; KIDNEY; MICE; MICE, NUDE; NF-KAPPA B; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHOPROTEINS; PROTEIN ARRAY ANALYSIS; PROTEOMICS; RATS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, LHRH; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRIPTORELIN PAMOATE;

EID: 84874034347     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-12-0192     Document Type: Article

References (41)

1. Acharya CR, Hsu DS, Anders CK, Anguiano A, Salter KH, Walters KS, Redman RC, Tuchman SA, Moylan CA, Mukherjee S et al. 2008 Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. Journal of the American Medical Association 299 1574-1587. (doi:10.1001/jama. 299.13.1574)
2. Angelucci C, Iacopino F, Lama G, Capucci S, Zelano G, Boca M, Pistilli A & Sica G 2004 Apoptosis-related gene expression affected by a GnRH analogue without induction of programmed cell death in LNCaP cells. Anticancer Research 24 2729-2738.
3. Astuti P, Pike T, Widberg C, Payne E, Harding A, Hancock J & Gabrielli B 2009 MAPK pathway activation delays G2/M progression by destabilizing Cdc25B. Journal of Biological Chemistry 284 33781-33788. (doi:10.1074/jbc.M109.027516)
4. Barboule N, Lafon C, Chadebech P, Vidal S & Valette A 1999 Involvement of p21 in the PKC-induced regulation of the G2/M cell cycle transition. FEBS Letters 444 32-37. (doi:10.1016/S0014-5793(99)00022-8)
5. Blankenstein MA, Henkelman MS & Klijn JG 1985 Direct inhibitory effect of a luteinizing hormone-releasing hormone agonist on MCF-7 human breast cancer cells. European Journal of Cancer & Clinical Oncology 21 1493-1499. (doi:10.1016/0277-5379(85)90244-5)
6. Breitling R, Armengaud P, Amtmann A & Herzyk P 2004 Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments. FEBS Letters 573 83-92. (doi:10.1016/j. febslet.2004.07.055)
7. Cho HJ, Park SM, Hwang EM, Baek KE, Kim IK, Nam IK, Im MJ, Park SH, Bae S, Park JY et al. 2010 Gadd45b mediates Fas-induced apoptosis by enhancing the interaction between p38 and retinoblastoma tumor suppressor. Journal of Biological Chemistry 285 25500-25505. (doi:10.1074/jbc.M109.091413)
8. Dangi S, Chen FM & Shapiro P 2006 Activation of extracellular signalregulated kinase (ERK) in G2 phase delays mitotic entry through p21CIP1. Cell Proliferation 39 261-279. (doi:10.1111/j.1365-2184.2006. 00388.x)
9. Dunning MJ, Smith ML, Ritchie ME & Tavare S 2007 beadarray: R classes and methods for Illumina bead-based data. Bioinformatics 23 2183-2184. (doi:10.1093/bioinformatics/btm311)
10. Eidne KA, Flanagan CA, Harris NS & Millar RP 1987 Gonadotropinreleasing hormone (GnRH)-binding sites in human breast cancer cell lines and inhibitory effects of GnRH antagonists. Journal of Clinical Endocrinology and Metabolism 64 425-432. (doi:10.1210/jcem-64-3-425)
11. Emons G, Pahwa GS, Brack C, Sturm R, Oberheuser F & Knuppen R 1989 Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata. European Journal of Cancer & Clinical Oncology 25 215-221. (doi:10.1016/0277-5379(89)90011-4)
12. Emons G, Schroder B, Ortmann O, Westphalen S, Schulz KD & Schally AV 1993a High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines. Journal of Clinical Endocrinology and Metabolism 77 1458-1464. (doi:10.1210/jc.77.6.1458)
13. Emons G, Ortmann O, Becker M, Irmer G, Springer B, Laun R, Holzel F, Schulz KD & Schally AV 1993b High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. Cancer Research 53 5439-5446.
14. Emons G, Grundker C, Gunthert AR, Westphalen S, Kavanagh J & Verschraegen C 2003 GnRH antagonists in the treatment of gynecological and breast cancers. Endocrine-Related Cancer 10 291-299. (doi:10.1677/erc.0.0100291)
15. Finch AR, Green L, Hislop JN, Kelly E & McArdle CA 2004 Signaling and antiproliferative effects of type I and II gonadotropin-releasing hormone receptors in breast cancer cells. Journal of Clinical Endocrinology and Metabolism 89 1823-1832. (doi:10.1210/jc.2003-030787)
16. Gentleman RC, Carey VJ, Bates DM, Bolstad B, DettlingM, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J et al. 2004 Bioconductor: open software development for computational biology and bioinformatics. Genome Biology 5 R80. (doi:10.1186/gb-2004-5-10-r80)
17. Grundker C, Schulz K, Gunthert AR & Emons G 2000 Luteinizing hormonereleasing hormone induces nuclear factor kappaB-activation and inhibits apoptosis in ovarian cancer cells. Journal of Clinical Endocrinology and Metabolism 85 3815-3820. (doi:10.1210/jc.85.10.3815)
18. Grundker C, Volker P & Emons G 2001 Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein alpha(I)-mediated activation of phosphotyrosine phosphatase. Endocrinology 142 2369-2380. (doi:10.1210/en.142.6.2369)
19. Grundker C, Gunthert AR, Millar RP & Emons G 2002 Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation. Journal of Clinical Endocrinology and Metabolism 87 1427-1430. (doi:10.1210/jc.87.3. 1427)
20. Huang da W, Sherman BT & Lempicki RA 2009 Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature Protocols 4 44-57. (doi:10.1038/nprot.2008.211)
21. Ihaka R & Gentleman R 1996 R: a language for data analysis and graphics. Journal of Computational and Graphical Statistics 5 299-314. (doi:10.2307/1390807)
22. Kakar SS,Winters SJ, ZachariasW,Miller DM & Flynn S 2003 Identification of distinct gene expression profiles associated with treatment of LbetaT2 cells with gonadotropin-releasing hormone agonist using microarray analysis. Gene 308 67-77. (doi:10.1016/S0378-1119 (03)00446-3)
23. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G & Kallioniemi OP 1998 Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nature Medicine 4 844-847. (doi:10.1038/nm0798-844)
24. Limonta P, Dondi D, Moretti RM, Maggi R & Motta M 1992 Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP. Journal of Clinical Endocrinology and Metabolism 75 207-212. (doi:10.1210/jc.75.1.207)
25. Limonta P,Marelli MM, Mai S,Motta M, Martini L&Moretti RM2012 GnRH receptors in cancer: from cell biology to novel targeted therapeutic strategies. Endocrine Reviews 33 784-811. (doi:10.1210/er.2012-1014)
26. Marini L, Iacopino F, Schinzari G, Robustelli della Cuna FS, Mantovani G & Sica G 1994 Direct antiproliferative effect of triptorelin on human breast cancer cells. Anticancer Research 14 1881-1885.
27. Maudsley S, Davidson L, Pawson AJ, Chan R, Lopez de Maturana R & Millar RP 2004 Gonadotropin-releasing hormone (GnRH) antagonists promote proapoptotic signaling in peripheral reproductive tumor cells by activating a Galphai-coupling state of the type I GnRH receptor. Cancer Research 64 7533-7544. (doi:10.1158/0008-5472.CAN-04-1360)
28. Mebratu Y & Tesfaigzi Y 2009 How ERK1/2 activation controls cell proliferation and cell death: is subcellular localization the answer? Cell Cycle 8 1168-1175. (doi:10.4161/cc.8.8.8147)
29. Miller WR, Scott WN, Morris R, Fraser HM & Sharpe RM 1985 Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature 313 231-233. (doi:10.1038/313231a0)
30. Moretti RM, Marelli MM, Dondi D, Poletti A, Martini L, Motta M & Limonta P 1996 Luteinizing hormone-releasing hormone agonists interfere with the stimulatory actions of epidermal growth factor in human prostatic cancer cell lines, LNCaP and DU 145. Journal of Clinical Endocrinology and Metabolism 81 3930-3937. (doi:10.1210/jc.81.11. 3930)
31. Morgan K, Stewart AJ, Miller N, Mullen P, Muir M, Dodds M, Medda F, Harrison D, Langdon S & Millar RP 2008 Gonadotropin-releasing hormone receptor levels and cell context affect tumor cell responses to agonist in vitro and in vivo. Cancer Research 68 6331-6340. (doi:10.1158/ 0008-5472.CAN-08-0197)
32. Morgan K, Stavrou E, Leighton SP, Miller N, Sellar R & Millar RP 2011a Elevated GnRH receptor expression plus GnRH agonist treatment inhibits the growth of a subset of papillomavirus 18-immortalized human prostate cells. Prostate 71 915-928. (doi:10.1002/pros.21308)
33. Morgan K, Meyer C, Miller N, Sims AH, Cagnan I, Faratian D, Harrison DJ, Millar RP & Langdon SP 2011b GnRH receptor activation competes at a low level with growth signaling in stably transfected human breast cell lines. BMC Cancer 11 476. (doi:10.1186/1471-2407-11-476)
34. Salisbury TB, Binder AK & Nilson JH 2008 Welcoming b-catenin to the gonadotropin-releasing hormone transcriptional network in gonadotropes. Molecular Endocrinology 22 1295-1303. (doi:10.1210/ me.2007-0515)
35. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S & Boyd MR 1990 New colorimetric cytotoxicity assay for anticancer-drug screening. Journal of the National Cancer Institute 82 1107-1112. (doi:10.1093/jnci/82.13.1107)
36. Spurrier B, Ramalingam S & Nishizuka S 2008 Reverse-phase protein lysate microarrays for cell signaling analysis. Nature Protocols 3 1796-1808. (doi:10.1038/nprot.2008.179)
37. Straus DS, Pascual G, Li M, Welch JS, Ricote M, Hsiang CH, Sengchanthalangsy LL, Ghosh G & Glass CK 2000 15-Deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. PNAS 97 4844-4849. (doi:10.1073/pnas.97.9.4844)
38. Taylor SS, Ha E &McKeon F 1998 The human homologue of Bub3 is required for kinetochore localization of Bub1 and a Mad3/Bub1-related protein kinase. Journal of Cell Biology 142 1-11. (doi:10.1083/jcb.142.1.1)
39. White CD, Coetsee M, Morgan K, Flanagan CA, Millar RP & Lu ZL 2008 A crucial role for Galphaq/11, but not Galphai/o or Galphas, in gonadotropin-releasing hormone receptor-mediated cell growth inhibition. Molecular Endocrinology 22 2520-2530. (doi:10.1210/me.2008-0122)
40. Zhu N, Shao Y, Xu L, Yu L & Sun L 2009 Gadd45-alpha and Gadd45-gamma utilize p38 and JNK signaling pathways to induce cell cycle G2/M arrest in Hep-G2 hepatoma cells. Molecular Biology Reports 36 2075-2085. (doi:10.1007/s11033-008-9419-9)
41. Zhuang S & Schnellmann RG 2006 A death-promoting role for extracellular signal-regulated kinase. Journal of Pharmacology and Experimental Therapeutics 319 991-997. (doi:10.1124/jpet.106.107367)